Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juni 2025

Genmab — Juni 2025

Planlagt Fastgjort Låst Flyttet Genmab
266 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #145

    Europa/aktier: Sundhedsaktier vinder frem mens investorer kigger mod toldforhandlinger https://proinvestor.com/investornyt/1325611/europa-aktier-sundhedsaktier-vinder-frem-mens-investorer-kigger-mod-toldforhandlinger

    1 Reply Last reply
    0
    • Legolas23L Offline
      Legolas23L Offline
      Legolas23
      wrote on sidst redigeret af
      #146

      FDA vil fremskynde godkendelsen af lægemidler til sjældne sygdomme https://medwatch.dk/Medicinal___Biotek/article18253942.ece?utm_campaign=MedWatch Middag&utm_content=2025-06-06&utm_medium=email&utm_source=medwatch

      1 Reply Last reply
      0
      • B Offline
        B Offline
        bikube
        wrote on sidst redigeret af
        #147

        Det er da positivt, at han vil sætte tempoet op, men hvis det går ud over sikkerheden i deres arbejde, er det jo ikke entydigt godt. Man kan vel så påregne, at der skal køres fase 4 på nogle godkendte stoffer.

        1 Reply Last reply
        0
        • G Offline
          G Offline
          gentogen
          wrote on sidst redigeret af
          #148

          Fra samme kilde.......https://medwatch.dk/Medicinal___Biotek/article18073152.ece

          1 Reply Last reply
          0
          • SolsenS Offline
            SolsenS Offline
            Solsen
            wrote on sidst redigeret af
            #149

            Lidt om samarbejdet med Lundbec https://www.researchgate.net/publication/392007308_Rational_selection_of_the_monoclonal_a-synuclein_antibody_amlenetug_Lu_AF82422_for_the_treatment_of_a-synucleinopathies/fulltext/683034fb6b5a287c3043f3cb/Rational-selection-of-the-monoclonal-a-synuclein-antibody-amlenetug-Lu-AF82422-for-the-treatment-of-a-synucleinopathies.pdf?origin=publication_detail&_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InByb2ZpbGUiLCJwYWdlIjoicHVibGljYXRpb25Eb3dubG9hZCIsInByZXZpb3VzUGFnZSI6InB1Y

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #150

              ..Lundbeck. Ved ikke om jeg rigtigt tror på stoffet 😉

              1 Reply Last reply
              0
              • P Offline
                P Offline
                ProinvestorNEWS
                wrote on sidst redigeret af
                #151

                Knock-Your-Socks-Off-News – June 2025 https://www.linkedin.com/pulse/knock-your-socks-off-news-june-2025-genmab-p3wze/

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #152

                  Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma https://www.sciencedirect.com/science/article/pii/S2473952925003143

                  1 Reply Last reply
                  0
                  • R Offline
                    R Offline
                    Raun
                    wrote on sidst redigeret af
                    #153

                    Biontech BNT116 -
                    https://x.com/EvanKirstel/status/1932149953184375160

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #154

                      Det bliver spændende at følge @Raun

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #155

                        the Ph3 Acasunlimab trial adding a lot of new recruitment centers https://clinicaltrials.gov/study/NCT06635824?tab=history&a=8&b=9&compareMode=sideBySide#version-content-panel

                        1 Reply Last reply
                        0
                        • W Offline
                          W Offline
                          w
                          wrote on sidst redigeret af
                          #156

                          AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength. Hæver fra 2566 til 2661kr

                          1 Reply Last reply
                          0
                          • W Offline
                            W Offline
                            w
                            wrote on sidst redigeret af
                            #157

                            Human Verification

                            favicon

                            (finimize.com)

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #158

                              Plus 100 new sites 🙂 And boost targets. Are we back on trac ?

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #159

                                In full swing... let's see if they can replicate the speed with which they executed on Epcoritamab... that went very fast (is going very fast i should say), but this they have to do alone...

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #160

                                  ASCO 2025 presentations via https://www.genmabmedicalaffairs.com/congress?filv1=17

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #161

                                    Looks like Rina-S also are running fast 🙂

                                    1 Reply Last reply
                                    0
                                    • SolsenS Offline
                                      SolsenS Offline
                                      Solsen
                                      wrote on sidst redigeret af
                                      #162

                                      I have been a little cautious on Acasunlimab after Biontech left. But there is a chance that Biontech where wrong.

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #163

                                        the fact that they started a Melanoma trial with Acasunlimab is a strong signal i would think

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #164

                                          Yes I agree.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper